结直肠癌
毒性
药品
医学
酪氨酸激酶抑制剂
血管内皮生长因子
表皮生长因子受体
耐火材料(行星科学)
化疗
药理学
癌症
肿瘤科
血管内皮生长因子受体
内科学
生物
天体生物学
作者
Kanchi Patell,Veronica Mears,Michael H. Storandt,Amit Mahipal
标识
DOI:10.1080/17425255.2024.2332364
摘要
Introduction Colorectal cancer (CRC) is the third most diagnosed cancer globally and despite therapeutic strides, the prognosis for patients with metastatic disease (mCRC) remains poor. Fruquintinib is an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) targeting VEGFR -1, -2, and -3, and has recently received approval by the U.S. Food and Drug Administration for treatment of mCRC refractory to standard chemotherapy, anti-VEGF therapy, and anti-epidermal growth factor receptor (EGFR) therapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI